Table 2 Comparison of immune contexture considering location according to survival outcome.
Parameters | Recurrent | Nonrecurrent | P | Deceased | Surviving | P |
|---|---|---|---|---|---|---|
Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | |||
(N = 11) | (N = 11) | (N = 12) | (N = 10) | |||
CD3 | ||||||
TC | ||||||
Intratumoral (i) | 40 ± 40.8 (2–118) | 95 ± 79.7 (5–195) | 0.005* | 31 ± 51.4 (2–118) | 102 ± 75.8 (4–195) | 0.13 |
Stromal (s) | 4 ± 2.0 (1–8) | 3 ± 4.8 (0–15) | 0.032* | 4 ± 2.0 (0–7) | 6 ± 4.6 (0–15) | 0.024* |
Both (i + s) | 71 ± 83.6 (14–246) | 207 ± 165.6 (9–420) | 0.004* | 103 ± 103 (12–349) | 219 ± 157 (9–420) | 0.10 |
IF | ||||||
Intratumoral (i) | 32 ± 38.1 (13–134) | 35 ± 62.0 (12–218) | 0.16 | 31 ± 43.4 (12–134) | 40 ± 60.4 (12–218) | 0.58 |
Stromal (s) | 19 ± 24.2 (2–72) | 95 ± 83.8 (3–220) | <0.001* | 15 ± 39.1 (2–134) | 65 ± 84.6 (6–220) | 0.007* |
Both (i + s) | 169 ± 70.2 (35–285) | 301 ± 157.4 (29–502) | 0.021* | 178 ± 93 (29–316) | 261 ± 162 (104–502) | 0.013* |
Total (TC + IF) | 234 ± 129 (100–531) | 576 ± 268 (41–876) | 0.022* | 237 ± 171 (41–606) | 554 ± 263 (150–876) | 0.09 |
CD8 | ||||||
TC | ||||||
Intratumoral (i) | 13 ± 12.0 (1–39) | 22 ± 51.6 (1–155) | <0.001* | 13 ± 17.4 (7–33) | 22 ± 54.2 (1–155) | 0.001* |
Stromal (s) | 1 ± 5.7 (0–20) | 1 ± 3.98 (0–12) | 0.96 | 1 ± 5.5 (0–3) | 4 ± 4.0 (0–20) | 0.94 |
Both (i + s) | 36 ± 25.2 (2–82) | 101 ± 107 (2–330) | 0.001* | 46 ± 34 (!2–132) | 99 ± 112 (2–330) | 0.001* |
IF | ||||||
Intratumoral (i) | 19 ± 9.2 (4–31) | 24 ± 33.4 (5–102) | 0.010* | 16 ± 9.5 (4–31) | 22 ± 34.4 (4–102) | 0.004* |
Stromal (s) | 17 ± 21.4 (2–78) | 20 ± 18.6 (1–61) | 0.98 | 16 ± 17.4 (11–61) | 18 ± 22.8 (4–31) | 0.52 |
Both (i + s) | 60 ± 48.9 (30–194) | 108 ± 75.7 (12–265) | 0.16 | 57 ± 37 (30–148) | 110 ± 81 (12–265) | 0.022* |
Total (TC + IF) | 102 ± 60 (53–246) | 207 ± 159 (59–482) | 0.007* | 110 ± 47 (55–195) | 215 ± 169 (53–482) | <0.001* |
Foxp3 | ||||||
TC | ||||||
Intratumoral (i) | 3 ± 11.7 (0–36) | 10 ± 21.9 (0–64) | 0.027* | 3 ± 5.1 (0–10) | 20 ± 12.5 (0–64) | 0.001* |
Stromal (s) | 0 ± 0.3 (0–2) | 0.5 ± 1.3 (0–4) | <0.001* | 1 ± 0.4 (0–1) | 1 ± 0.1 (0–4) | <0.001* |
Both (i + s) | 16 ± 23.7 (0–73) | 41 ± 45.7 (0–135) | 0.026* | 9 ± 14 (!2–132) | 51 ± 44 (2–135) | 0.001* |
IF | ||||||
Intratumoral (i) | 4 ± 9.1 (1–32) | 9 ± 20.0 (1–73) | 0.30 | 4 ± 8.3 (1–15) | 8 ± 20.8 (1–73) | 0.23 |
Stromal (s) | 1 ± 1.4 (0–4) | 1 ± 2.6 (0–6) | 0.026* | 1 ± 1.3 (0–4) | 2 ± 2.6 (0–6) | 0.009* |
Both (i + s) | 9 ± 20.2 (2–70) | 20 ± 42.8 (2–157) | 0.37 | 15 ± 19 (2–70) | 33 ± 44 (2–157) | 0.26 |
Total (TC + IF) | 32 ± 40 (2–121) | 73 ± 71 (2–216) | 0.06 | 25 ± 33 (4–216) | 85 ± 70 (4–216) | 0.015* |
Foxp3/CD8 ratio | ||||||
TC | ||||||
Intratumoral (i) | 13.5 ± 12.0 (1–39) | 22 ± 51.3 (1–155) | <0.001* | 13 ± 17 (5–65) | 22 ± 54 (1–155) | 0.001* |
Stromal (s) | 3.5 ± 11.7 (0–36) | 10 ± 22.0 (0–64) | 0.027* | 2 ± 7 (0–25) | 20.50 ± 21 (1–64) | 0.001* |
Both (i + s) | 1.75 ± 1.0 (0–18.25) | 5 ± 2 (0–33.75) | 0.026* | 1 ± 1.8 (0.0–12.75) | 11.5 ± 10 (0.5–33.75) | 0.001* |
IF | ||||||
Intratumoral (i) | 0.28 ± 0.4 (0–1) | 0.39 ± 0.7 (0–2) | 0.14 | 0.26 ± 0.6 (0–2) | 0.38 ± 0.5 (0–2) | 0.25 |
Stromal (s) | 0 1 ± 0.5 (0–2) | 0.01 ± 0.3 (0–1) | 0.45 | 0 ± 0.4 (0–2) | 0.1 ± 0.2 (0–1) | 0.55 |
Both (i + s) | 0.18 ± 0.1 (0.02–1.38) | 0.27 ± 0.1 (0.02–1.17) | 0.92 | 0.15 ± 0.5 (0.02–1.38) | 0.27 ± 0.3 (0.06–1.17) | 0.13 |
Total (TC + IF) | 0.96 ± 0.5 (0.05–9.31) | 2.83 ± 1.7 (0.01–17.01) | 0.035* | 0.72 ± 0.5 (0.01–7.06) | 5.95 ± 6.8 (0.28–17.01) | 0.001* |
CD68 | ||||||
TC | ||||||
Intratumoral (i) | 23 ± 15.3 (6–87) | 51 ± 52.0 (5–89) | 0.94 | 33 ± 29.8 (9–87) | 36 ± 25.4 (5–89) | 0.49 |
Stromal (s) | 3 ± 8.0 (1–4) | 6 ± 9.1 (1–18) | 0.012* | 4 ± 2.3 (1–10) | 5 ± 4.9 (1–18) | 0.07 |
Both (i + s) | 70 ± 55.1 (16–181) | 113 ± 55.1 (11–188) | 0.97 | 71 ± 53 (23–188) | 94 ± 61 (11–186) | 0.41 |
IF | ||||||
Intratumoral (i) | 20 ± 27.3 (6–55) | 38 ± 27.0 (10–175) | 0.016* | 23 ± 21 (10–55) | 35 ± 55 (6–175) | 0.046* |
Stromal (s) | 5 ± 1.0 (2–23) | 10 ± 4.7 (5–36) | 0.79 | 5 ± 10.5 (2–36) | 10 ± 5.8 (2–23) | 0.14 |
Both (i + s) | 59 ± 28.9 (24–130) | 119 ± 103.4 (29–375) | 0.019* | 77 ± 44 (24–175) | 133 ± 110 (40–375) | 0.06 |
Total (TC + IF) | 339 ± 211 (147–853) | 504 ± 592 (132–1829) | 0.008* | 351 ± 143 (150–543) | 785 ± 623 (132–1829) | 0.001* |
CD163 | ||||||
TC | ||||||
Intratumoral (i) | 55 ± 61.0 (7–207) | 91 ± 65.2 (8–229) | 0.93 | 76 ± 58 (7–207) | 75 ± 69.7 (15–229) | 0.54 |
Stromal (s) | 5 ± 3.2 (4–15) | 8 ± 4.1 (4–18) | 0.36 | 5 ± 4.4 (4–18) | 7 ± 2.8 (4–13) | 0.26 |
Both (i + s) | 120 ± 52 (40–429) | 198 ± 31 (51–467) | 0.90 | 162 ± 52 (40–429) | 162 ± 64 (47–462) | 0.46 |
IF | ||||||
Intratumoral (i) | 30 ± 21.0 (6–82) | 49 ± 36.1 (16–117) | 0.028* | 24 ± 21.5 (6–46) | 32 ± 36.8 (16–116) | 0.013* |
Stromal (s) | 16 ± 14.3 (5–50) | 23 ± 28.5 (3–80) | 0.03* | 13 ± 21.5 (3–73) | 7 ± 24.8 (4–80) | 0.83 |
Both (i + s) | 89 ± 35.8 (41–176) | 162 ± 79.1 (45–253) | 0.005* | 91 ± 47 (41–181) | 121 ± 83 (48–253) | 0.004* |
Total (TC + IF) | 1171 ± 723 (463–2838) | 2402 ± 1935 (406–5978) | 0.009* | 1086 ± 481 (463–1820) | 2578 ± 2026 (406–5978) | 0.001* |
Total | ||||||
Total TIL (CD3 + CD8 + Foxp3) | ||||||
TC | 113 ± 114.2 (23–361) | 375 ± 279.6 (13–885) | 0.007* | 110 ± 134 (31–481) | 368 ± 278 (13–885) | 0.001* |
IF | 238 ± 85.4 (87–350) | 460 ± 245.6 (104–886) | 0.003* | 254 ± 116 (89–495) | 394 ± 245 (182–886) | 0.007* |
TC + IF | 351 ± 185 (185–689) | 751 ± 485 (135–1524) | 0.049* | 410 ± 208 (135–793) | 803 ± 416 (216–1524) | 0.037* |
Total TAM (CD68 + CD163) | ||||||
TC | 223 ± 164 (63–587) | 315 ± 160 (75–591) | 0.96 | 269 ± 160 (68–587) | 266 ± 178 (63–591) | 0.63 |
IF | 142 ± 50.9 (103–267) | 300 ± 137.9 (74–588) | 0.07 | 180 ± 82 (74–332) | 272 ± 148 (105–588) | 0.14 |
TC + IF | 1535 ± 934 (613–3691) | 3139 ± 2527 (536–7807) | 0.009* | 1437 ± 624 (613–2329) | 3363 ± 2649 (538–7807) | 0.001* |
